Medicamen Biotech Limited
Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, sells, and distributes pharmaceutical formulations in India and internationally. The company offers drugs in various forms, including tablet, capsule, syrups, oral solution, and drops. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-… Read more
Medicamen Biotech Limited (MEDICAMEQ) - Net Assets
Latest net assets as of September 2025: ₹2.75 Billion INR
Based on the latest financial reports, Medicamen Biotech Limited (MEDICAMEQ) has net assets worth ₹2.75 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹3.67 Billion) and total liabilities (₹916.99 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹2.75 Billion |
| % of Total Assets | 75.02% |
| Annual Growth Rate | 18.42% |
| 5-Year Change | 60.12% |
| 10-Year Change | 1088.14% |
| Growth Volatility | 39.87 |
Medicamen Biotech Limited - Net Assets Trend (2006–2025)
This chart illustrates how Medicamen Biotech Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medicamen Biotech Limited (2006–2025)
The table below shows the annual net assets of Medicamen Biotech Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹2.13 Billion | +2.80% |
| 2024-03-31 | ₹2.07 Billion | +7.02% |
| 2023-03-31 | ₹1.93 Billion | +32.05% |
| 2022-03-31 | ₹1.46 Billion | +10.22% |
| 2021-03-31 | ₹1.33 Billion | +9.63% |
| 2020-03-31 | ₹1.21 Billion | +39.92% |
| 2019-03-31 | ₹866.34 Million | +16.12% |
| 2018-03-31 | ₹746.08 Million | +178.59% |
| 2017-03-31 | ₹267.81 Million | +49.54% |
| 2016-03-31 | ₹179.09 Million | +4.21% |
| 2015-03-31 | ₹171.85 Million | +3.91% |
| 2014-03-31 | ₹165.38 Million | +5.22% |
| 2013-03-31 | ₹157.17 Million | -21.81% |
| 2012-03-31 | ₹201.01 Million | -1.52% |
| 2011-03-31 | ₹204.12 Million | +25.53% |
| 2010-03-31 | ₹162.61 Million | +25.47% |
| 2009-03-31 | ₹129.60 Million | +11.89% |
| 2008-03-31 | ₹115.83 Million | +14.99% |
| 2007-03-31 | ₹100.73 Million | +17.58% |
| 2006-03-31 | ₹85.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medicamen Biotech Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 96307700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹963.08 Million | 45.26% |
| Common Stock | ₹127.15 Million | 5.98% |
| Other Comprehensive Income | ₹17.19 Million | 0.81% |
| Other Components | ₹1.02 Billion | 47.96% |
| Total Equity | ₹2.13 Billion | 100.00% |
Medicamen Biotech Limited Competitors by Market Cap
The table below lists competitors of Medicamen Biotech Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pacific Online Limited
PINK:PCOLF
|
$16.47 Million |
|
HCT Co. Ltd
KQ:072990
|
$16.47 Million |
|
WiseChip Semiconductor
TWO:5245
|
$16.47 Million |
|
REDCO PRP GROUP LTD -05
F:8KI
|
$16.48 Million |
|
Daesung Eltec Co. Ltd
KQ:025440
|
$16.45 Million |
|
Enzo Biochem Inc
NYSE:ENZ
|
$16.44 Million |
|
PT TBS Energi Utama Tbk
F:6AU
|
$16.44 Million |
|
TRF Limited
NSE:TRF
|
$16.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medicamen Biotech Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,069,843,000 to 2,127,809,000, a change of 57,966,000 (2.8%).
- Net income of 71,082,000 contributed positively to equity growth.
- Dividend payments of 12,715,000 reduced retained earnings.
- New share issuances of 8,650,000 increased equity.
- Other comprehensive income increased equity by 5,282,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹71.08 Million | +3.34% |
| Dividends Paid | ₹12.71 Million | -0.6% |
| Share Issuances | ₹8.65 Million | +0.41% |
| Other Comprehensive Income | ₹5.28 Million | +0.25% |
| Other Changes | ₹-14.33 Million | -0.67% |
| Total Change | ₹- | 2.80% |
Book Value vs Market Value Analysis
This analysis compares Medicamen Biotech Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.64x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 24.81x to 1.64x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹11.09 | ₹275.20 | x |
| 2007-03-31 | ₹13.04 | ₹275.20 | x |
| 2008-03-31 | ₹15.04 | ₹275.20 | x |
| 2009-03-31 | ₹16.78 | ₹275.20 | x |
| 2010-03-31 | ₹21.06 | ₹275.20 | x |
| 2011-03-31 | ₹26.42 | ₹275.20 | x |
| 2012-03-31 | ₹25.45 | ₹275.20 | x |
| 2013-03-31 | ₹18.77 | ₹275.20 | x |
| 2014-03-31 | ₹19.48 | ₹275.20 | x |
| 2015-03-31 | ₹19.03 | ₹275.20 | x |
| 2016-03-31 | ₹18.06 | ₹275.20 | x |
| 2017-03-31 | ₹25.69 | ₹275.20 | x |
| 2018-03-31 | ₹66.62 | ₹275.20 | x |
| 2019-03-31 | ₹74.06 | ₹275.20 | x |
| 2020-03-31 | ₹99.22 | ₹275.20 | x |
| 2021-03-31 | ₹108.78 | ₹275.20 | x |
| 2022-03-31 | ₹119.89 | ₹275.20 | x |
| 2023-03-31 | ₹155.28 | ₹275.20 | x |
| 2024-03-31 | ₹163.50 | ₹275.20 | x |
| 2025-03-31 | ₹167.49 | ₹275.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medicamen Biotech Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.37%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 1.40x
- Recent ROE (3.34%) is below the historical average (7.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | 17.44% | 2.87% | 1.54x | 3.95x | ₹6.38 Million |
| 2007 | 14.95% | 2.51% | 1.29x | 4.61x | ₹4.99 Million |
| 2008 | 13.04% | 1.96% | 1.49x | 4.47x | ₹3.52 Million |
| 2009 | 10.63% | 1.60% | 1.88x | 3.53x | ₹812.51K |
| 2010 | 24.45% | 3.91% | 1.76x | 3.55x | ₹23.50 Million |
| 2011 | 13.60% | 2.26% | 1.76x | 3.43x | ₹7.36 Million |
| 2012 | -4.10% | -0.82% | 1.46x | 3.43x | ₹-28.35 Million |
| 2013 | -31.35% | -7.70% | 0.98x | 4.15x | ₹-64.99 Million |
| 2014 | 0.57% | 0.13% | 1.13x | 3.90x | ₹-15.60 Million |
| 2015 | 2.56% | 0.57% | 1.13x | 4.00x | ₹-12.78 Million |
| 2016 | 2.69% | 0.71% | 1.12x | 3.35x | ₹-13.10 Million |
| 2017 | 19.27% | 6.26% | 1.12x | 2.74x | ₹24.82 Million |
| 2018 | 13.55% | 9.07% | 0.95x | 1.58x | ₹26.52 Million |
| 2019 | 13.88% | 9.81% | 0.90x | 1.58x | ₹33.62 Million |
| 2020 | 10.96% | 10.59% | 0.69x | 1.50x | ₹11.70 Million |
| 2021 | 9.13% | 10.76% | 0.58x | 1.46x | ₹-11.60 Million |
| 2022 | 10.17% | 12.90% | 0.51x | 1.54x | ₹2.51 Million |
| 2023 | 7.67% | 10.54% | 0.51x | 1.44x | ₹-44.97 Million |
| 2024 | 5.28% | 6.10% | 0.61x | 1.42x | ₹-97.67 Million |
| 2025 | 3.34% | 4.37% | 0.55x | 1.40x | ₹-141.70 Million |
Industry Comparison
This section compares Medicamen Biotech Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $17,182,683,300
- Average return on equity (ROE) among peers: 11.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medicamen Biotech Limited (MEDICAMEQ) | ₹2.75 Billion | 17.44% | 0.33x | $16.46 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $366.97 Million | 3.51% | 2.41x | $11.49 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $2.27 Million | -2.03% | 0.10x | $351.56 Million |
| Abbott India Limited (ABBOTINDIA) | $11.96 Billion | 21.35% | 0.35x | $1.60 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $37.90 Billion | 24.28% | 0.32x | $1.51 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.79 Million |
| Albert David Limited (ALBERTDAVD) | $1.86 Billion | 5.29% | 0.56x | $16.25 Million |
| Alivus Life Sciences Limited (ALIVUS) | $21.38 Billion | 21.84% | 0.26x | $329.34 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $1.71 Billion | 11.38% | 0.30x | $5.51 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $964.67 Million | 9.99% | 0.49x | $81.74 Million |